Axtria

Agentic AI promises to revolutionize the pharma landscape by reimagining business processes through a combination of human intelligence and agent agility. As we embrace this technology, we stand at the cusp of a new era in pharmaceutical excellence, where the human-agent partnership will drive unprecedented commercial success. Unlike traditional AI, agentic systems are proactive, goal-directed, and capable of orchestrating complex, multi-step tasks with minimal human intervention. From accelerating insights in Commercial and Medical Affairs to transforming patient engagement and optimizing clinical workflows, Agentic AI holds the potential to radically redefine pharma operations. In this webinar, join Sudip Chakraborty, Head of AI/GenAI, and Sameer Sardana, Head of GenAI Products from Axtria, a leading pharma consulting and products firm, as we explore how Agentic AI is reshaping the industry. We will share current trends, practical use cases, key capabilities needed, and an implementation roadmap. Discover how our purpose-built agents and Axtria InsightsMax™ platform can help you move beyond experimentation and fast-track your journey to scalable, measurable impact.

Speakers:
Sudip Chakraborty, Head of AI/Gen AI, Axtria
Sameer Sardana, Head of GenAI Products, Axtria

Even as digital investments increase, the field force remains the primary means of customer engagement for pharma companies and is their biggest promotional investment. As a means of providing guidance to the field, traditional call planning occurs infrequently and in cycles, oftentimes failing to incorporate the latest data available to drive rep activity and customer interactions. Dynamic Targeting leverages digital investments by bringing data and insights to the field force in a more timely manner, enabling more real-time, data driven decisions. Using the latest customer and data insights, Dynamic Targeting provides clear, effective, guidance to empower field teams to optimize brand reach and drive exceptional customer engagement.

In this webinar, we will explore the following with industry leaders Stephanie Odutola and Owen Morris from AstraZeneca:

• Laying the groundwork: defining Traditional Call Planning, Next Best Action, and Dynamic Targeting
• Ensuring stakeholder buy-in
• Evolving the Commercial Operations function to support Dynamic Targeting
• Overcoming the barriers to Dynamic Targeting adoption
• Measuring the impact of Dynamic Targeting
• Making the leap from Dynamic Targeting to full Omnichannel Orchestration

Pharma’s investment in digital has grown significantly in the last few years, fueled by the proliferation of digital channels and evolving customer preferences. This has made customer journeys very complex, with customers choosing how and where to interact with your brand in a unique and on-demand manner. With these trends in play, we must ensure a holistic measurement approach towards measuring and optimizing omnichannel campaigns.

In this webinar, we discuss orchestrating various analytical approaches, such as Marketing Mix Modeling, attribution modeling, and campaign analytics in tandem at varying cadences to enable outcomes-driven omnichannel campaigns. We will also discuss how Marketing Mix outputs must evolve to inform downstream Next Best Action recommendations.

The amount of data available across marketing channels has exploded in recent times, leading to information overload without true insights. Our panel of experts with extensive experience in storytelling and insight mining will discuss how complex data can deliver easily understandable insights that drive action.

Panelists:

• Robert (Bob) Allen, Lead, Worldwide Engagement & Channel Planning, US/Canada Oncology at Bristol Myers Squibb
• Lisa Hernandez, Senior Director, US Omnichannel Marketing, Daiichi Sankyo Inc.
• Siva Tallavajhala, Director, Omnichannel Mktg Innovation & Development COE, Menarini-Stemline
• Vandana Singh, Principal, Omnichannel Practice, Axtria
• Devesh Verma, Principal, Omnichannel expert, Axtria

The coronavirus pandemic and responses in battling COVID-19 have created never-before-seen challenges for the pharma industry, such as public policy mandates (e.g., shelter-in-place orders, closing of non-essential businesses) and sweeping restrictions placed on industry representatives from entering offices and hospitals to see HCPs. These policy mandates and restrictions have generated an unprecedented adverse economic situation and caused companies to rethink their Go-To-Market strategy. The International Monetary Fund recently noted in their April 2020 World Economic Outlook, “The Great Lockdown. The world economy will experience the worst recession since the Great Depression.”

This webinar will conduct a strategic view on how the generation of economic effects from policy responses to COVID-19 are reflected through two critical processes: brand financial forecasting and marketing-mix analysis.

• Part 1: Discuss and measure how brand financial forecasts can be adversely affected by COVID-19. We will demonstrate the development of an urban-level econometrically estimated inferential new prescription brand model, specified with management control and economic variables. This model is then used to predict generated drag effects on brand financial forecasts from a COVID-19 recession. The prediction model will also show how changes in sales, marketing, and payer-related channels can be implemented and measured to mitigate brand financial drag effects.
• Part 2: Examine how a deep recession and continued industry representative access restrictions to see HCPs affect the optimal mix of commercialization activities. Pharma sales and marketing is evolving due to COVID-19, such as changes in sales rep access restrictions at physician offices and hospitals, greater use of digital channels to compensate for this decline in access to continue sales rep/HCP engagement, use of digital channels by HCPs as a means to acquire product information, potential changes in DTC spending to reflect patients decreasing their visits to their doctor, and a greater use of samples, copay cards, and other support programs to meet patient affordability and loss of insurance issues caused by the recession. Subject to caveats that pretty much everything is a bit uncertain (this is the first global pandemic for most of the living population), these changes will be analyzed by how they affect marketing mix optimization, scenario planning for budget allocation, and the measurement of budget trade-offs.

Presenters:

• George Chressanthis, PhD, Principal Scientist, Axtria
• Vipul Pandey, MBA, Director, Decision Science, Axtria
• David Wood, PhD, Senior Principal, Axtria

The COVID-19 pandemic has impacted every walk of life, and businesses are still in the midst of evaluating the pandemic’s impact and mitigating potential losses during these times. The pharmaceutical industry, which is at the forefront of finding an effective cure for the pandemic, has also faced challenges. The industry needs to explore innovative ways to engage with its core customer groups (including patients, prescribers, and payers).

Even before the pandemic hit the globe, the pharmaceutical industry was grappling with the notion of enabling omnichannel strategies to engage with key customers. As the pandemic has resulted in complete lockdown on sales rep access to physician offices, the industry has been forced to devise an omnichannel engagement strategy “on-the-fly.” Most companies had to set up remote detailing capability in their reps’ CRM platforms. But omnichannel engagement goes beyond just remote or virtual detailing – it also requires changing the focus from the brand/campaign to the customer.

In this webinar, Axtria will review the current trends toward omnichannel migration in the industry. The webinar will discuss how the customers of the pharmaceutical industry (i.e., patients, prescribers, and payers) have embraced omnichannel to connect with each other and how the industry needs to adapt to meet needs based on customer-preferred channels. The webinar will also cover new approaches to using population mobility information to devise a differentiated omnichannel strategy during the time when local economies start to open up. Axtria will also recommend a path for pharmaceutical companies to transition their traditional multichannel planning approach to an orchestrated omnichannel planning approach.

Presenters:

• Dhaval Mukhatyar, Senior Director, Axtria
• Bob Mozenter, MS, MBA, Director, Marketing Solutions, Axtria
• Devesh Verma, PhD, Principal, Axtria

Life Sciences companies are grappling with the huge impacts that the global coronavirus pandemic is creating for day-to-day lives, health systems, and the global economy. Countries and localities have instituted travel bans and social distancing mandates, including closing non-essential businesses, to help contain the spread of the virus. In-person access to healthcare providers has been limited to just patients seeking treatment. While some of these measures are likely shorter-term in nature, experts are predicting longer-term impacts throughout 2020.

Pharma companies, and their sales forces in particular, are seeing huge disruptions. Access to health care providers is reduced or eliminated in much of the world, sidelining sales reps from their normal personal promotion work. Companies are grappling with how to proactively manage these key employees (and this key asset), considering the full sales operations landscape and incentive compensation (IC) plans, during these unusual circumstances.

In this webinar session, Axtria will:

• Provide an overview of how COVID-19 is disrupting the sales force and impacting all sales operations areas, with a focus on IC.
• Discuss the key objectives sales operations leaders are focused on when considering IC changes, including employee safety, sales force engagement, and effective use of IC budgets.
• Look at the IC levers available to sales operations leaders while managing the impact of COVID-19 from a short-term, medium-term, and long-term perspective.
• Review some of the commonly used tactics and strategies that pharma companies are embracing in these unprecedented times.

Presenters:

• Asheesh Sharma, Head Commercial Excellence, Axtria
• Daniel Stewart, Director, Axtria
• Abhijit (Abhi) Paul, Director, Axtria

Pharma companies are evolving to deliver a true omnichannel experience to their key customers. While it is crucial to develop both a personal and non-personal engagement plan for a multichannel strategy, a vital missing component is to connect next-best interactions and associated messaging across channels to create a harmonized omnichannel experience.

While a rep promotes his/her brand to an HCP, it is not common for the rep to discuss the brand’s digital presence, such as a published whitepaper or upcoming webinar to ensure prescribers are on-board digital channels. On the other end, brand marketers make considerable investments to engage customers using non-personal channels, but have no direct influence or control on the personal channel.

In this webinar series, we will review key challenges of interweaving personal and non-personal promotion to build an omnichannel customer engagement strategy. We will discuss ways to leverage AI/ML techniques to mine insights from complex and messy data and convert these insights to next-best-actions (NBAs) for sales professionals and other marketing channel providers. We will examine digital analytics KEY performance metrics and share an example of how these can be optimized for an email campaign for HCPs or patients. We will also showcase pharma industry-based case studies covering: customer journeys (across multiple digital channels, the journey analytics, and its impact on CX), and the power of AI/ML-based NBA suggestions in enhancing CX.

Part 2 will be focused on operationalizing omnichannel marketing.

Presenters:

• Devesh Verma and Geeta Padbidri, Axtria (Part 1)
• Robert Mozenter and Ilker Oruc, Axtria (Part 2)

Pharma companies are evolving to deliver a true omnichannel experience to their key customers. While it is crucial to develop both a personal and non-personal engagement plan for a multichannel strategy, a vital missing component is to connect next-best interactions and associated messaging across channels to create a harmonized omnichannel experience.

While a rep promotes his/her brand to an HCP, it is not common for the rep to discuss the brand’s digital presence, such as a published whitepaper or upcoming webinar to ensure prescribers are on-board digital channels. On the other end, brand marketers make considerable investments to engage customers using non-personal channels, but have no direct influence or control on the personal channel.

In this webinar series, we will review key challenges of interweaving personal and non-personal promotion to build an omnichannel customer engagement strategy. We will discuss ways to leverage AI/ML techniques to mine insights from complex and messy data and convert these insights to next-best-actions (NBAs) for sales professionals and other marketing channel providers. We will examine digital analytics KEY performance metrics and share an example of how these can be optimized for an email campaign for HCPs or patients. We will also showcase pharma industry-based case studies covering: customer journeys (across multiple digital channels, the journey analytics, and its impact on CX), and the power of AI/ML-based NBA suggestions in enhancing CX.

Part 1 will introduce a omnichannel customer engagement paradigm.

Presenters:

• Devesh Verma and Geeta Padbidri, Axtria (Part 1)
• Robert Mozenter and Ilker Oruc, Axtria (Part 2)

In the last few years, many companies have started to implement AI/ML practices to elevate user experience. Common examples of AI/ML include movie recommendations on Netflix, self-drive cars from Google, and photo tagging face recognition on Facebook. Pharmaceutical companies are also exploring ways to leverage AI/ML to improve the efficiency of their Operations and Sales teams. For example, AI/ML techniques can be used to perform early-stage error detection during data ingestion processes, leading to significant time and cost reductions. Additionally, AI/ML techniques can be utilized to increase the efficiency and effectiveness of sales representatives by providing them suggestions on next best actions. Throughout this session, we will be covering use cases of advanced AI/ML techniques to help pharmaceutical companies answer three key questions when working on Commercial Operations projects:

• How can AI/ML techniques help improve incentive compensation execution?
• How can AI/ML assist the sales reps in determining the next best target to call on?
• How can AI/ML help with optimizing territory alignments?

Presenters:

• Tej Pandey, Lead, Commercial Excellence, Axtria;
• Ellie Houck, Consultant, Commercial Excellence, Axtria; and Landi Huang, Consultant, Commercial Excellence, Axtria